Literature DB >> 28660888

Use of a gamma-2 herpesvirus as a vector to deliver antibodies to rhesus monkeys.

G F Bischof1,2, Y C Shin1, S P Fuchs1,2, J M Martinez-Navio1, W A Lauer1, E G Rakasz3, R C Desrosiers1.   

Abstract

The gamma-2 herpesvirus of rhesus monkeys, rhesus monkey rhadinovirus (RRV), persists principally in B cells of its host. We constructed recombinant strains of RRV expressing the rhesus monkey-derived anti-SIV monoclonal antibodies 4L6 and 5L7 and compared the RRV-mediated in vivo delivery of these antibodies in rhesus monkeys with previous studies that utilized intramuscular delivery with an adeno-associated virus (AAV) vector. Recombinant RRV-4L6 and RRV-5L7 were both shown to stably produce the antibodies in persistently infected B-cell lines in culture. Two RRV-negative rhesus monkeys were experimentally infected with recombinant RRV-4L6 and two with recombinant RRV-5L7. Following infection, the appearance of the delivered antibody was readily detected in all four animals. However, the levels of the delivered antibody were considerably lower than what has been typically observed following intramuscular AAV delivery. Furthermore, three of the four monkeys had an antibody response to the delivered antibody as had been observed previously with intramuscular AAV delivery of these same antibodies. We conclude that this recombinant herpesvirus has no inherent advantage over AAV for delivery of potentially therapeutic monoclonal antibodies in a rhesus monkey model.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28660888      PMCID: PMC6258056          DOI: 10.1038/gt.2017.49

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  38 in total

1.  The primary sequence of rhesus monkey rhadinovirus isolate 26-95: sequence similarities to Kaposi's sarcoma-associated herpesvirus and rhesus monkey rhadinovirus isolate 17577.

Authors:  L Alexander; L Denekamp; A Knapp; M R Auerbach; B Damania; R C Desrosiers
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1.

Authors:  Christine Armbruster; Gabriela M Stiegler; Brigitta A Vcelar; Walter Jäger; Nelson L Michael; Norbert Vetter; Hermann W D Katinger
Journal:  AIDS       Date:  2002-01-25       Impact factor: 4.177

3.  Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection.

Authors:  Kevin O Saunders; Amarendra Pegu; Ivelin S Georgiev; Ming Zeng; M Gordon Joyce; Zhi-Yong Yang; Sung-Youl Ko; Xuejun Chen; Stephen D Schmidt; Ashley T Haase; John-Paul Todd; Saran Bao; Peter D Kwong; Srinivas S Rao; John R Mascola; Gary J Nabel
Journal:  J Virol       Date:  2015-03-18       Impact factor: 5.103

4.  Whole-genome transcription profiling of rhesus monkey rhadinovirus.

Authors:  Dirk P Dittmer; Carlos M Gonzalez; Wolfgang Vahrson; Scott M DeWire; Rebecca Hines-Boykin; Blossom Damania
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

5.  Rhesus rhadinovirus establishes a latent infection in B lymphocytes in vivo.

Authors:  E P Bergquam; N Avery; S M Shiigi; M K Axthelm; S W Wong
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

6.  Importance of codon usage for the temporal regulation of viral gene expression.

Authors:  Young C Shin; Georg F Bischof; William A Lauer; Ronald C Desrosiers
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-26       Impact factor: 11.205

7.  Broad neutralization coverage of HIV by multiple highly potent antibodies.

Authors:  Laura M Walker; Michael Huber; Katie J Doores; Emilia Falkowska; Robert Pejchal; Jean-Philippe Julien; Sheng-Kai Wang; Alejandra Ramos; Po-Ying Chan-Hui; Matthew Moyle; Jennifer L Mitcham; Phillip W Hammond; Ole A Olsen; Pham Phung; Steven Fling; Chi-Huey Wong; Sanjay Phogat; Terri Wrin; Melissa D Simek; Wayne C Koff; Ian A Wilson; Dennis R Burton; Pascal Poignard
Journal:  Nature       Date:  2011-09-22       Impact factor: 49.962

8.  AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges.

Authors:  Matthew R Gardner; Lisa M Kattenhorn; Hema R Kondur; Markus von Schaewen; Tatyana Dorfman; Jessica J Chiang; Kevin G Haworth; Julie M Decker; Michael D Alpert; Charles C Bailey; Ernest S Neale; Christoph H Fellinger; Vinita R Joshi; Sebastian P Fuchs; Jose M Martinez-Navio; Brian D Quinlan; Annie Y Yao; Hugo Mouquet; Jason Gorman; Baoshan Zhang; Pascal Poignard; Michel C Nussenzweig; Dennis R Burton; Peter D Kwong; Michael Piatak; Jeffrey D Lifson; Guangping Gao; Ronald C Desrosiers; David T Evans; Beatrice H Hahn; Alexander Ploss; Paula M Cannon; Michael S Seaman; Michael Farzan
Journal:  Nature       Date:  2015-02-18       Impact factor: 49.962

9.  AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing Activity.

Authors:  Sebastian P Fuchs; José M Martinez-Navio; Michael Piatak; Jeffrey D Lifson; Guangping Gao; Ronald C Desrosiers
Journal:  PLoS Pathog       Date:  2015-08-06       Impact factor: 6.823

Review 10.  Broadly Neutralizing Antibodies for HIV Eradication.

Authors:  Kathryn E Stephenson; Dan H Barouch
Journal:  Curr HIV/AIDS Rep       Date:  2016-02       Impact factor: 5.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.